Method for breast cancer recurrence prediction under endocrine treatment

US10577661B2 · kind B2 · utility

Assignee

• MYRIAD INTERNATIONAL GMBH · DE

Inventors

• Mareike Dartmann · Cologne, DE
• Inke Sabine Feder · Leverkusen, DE
• Mathias Gehrmann · Tönisvorst, DE
• Guido Hennig · Wynau, CH
• Karsten Weber · Leutenbach, DE
• Christian Von Törne · Cologne, DE
• Ralf Kronenwett · Cologne, DE
• Christoph Petry · Cologne, DE

Key dates

• Filing date: Aug 11, 2016
• Grant date: Mar 3, 2020
• Expiry date: Oct 12, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/158
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising:(a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP(b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.